EXACT SCIENCES CORP (EXAS) EBIT (2010 - 2025)

Exact Sciences (EXAS) has reported EBIT for 16 consecutive years, with -$82.6 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, EBIT rose 90.58% year-over-year to -$82.6 million in Q4 2025; TTM through Dec 2025 was -$206.3 million, a 80.33% increase from a year earlier, with the FY2025 full-year figure at -$206.3 million, up 80.33% from the prior year.
• EBIT was -$82.6 million for Q4 2025 at Exact Sciences, down from -$25.5 million in the prior quarter.
• Over five years, EBIT peaked at $6.8 million in Q3 2023 and troughed at -$876.4 million in Q4 2024.
• A 5-year average of -$146.0 million and a median of -$101.4 million in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT soared 104.96% in 2023 and tumbled 1191.77% in 2024, its largest moves.
• Over 5 years, EBIT stood at -$221.4 million in 2021, then surged by 46.32% to -$118.9 million in 2022, then jumped by 42.93% to -$67.8 million in 2023, then plunged by 1191.77% to -$876.4 million in 2024, then jumped by 90.58% to -$82.6 million in 2025.
• The last three EBIT figures came in at -$82.6 million (Q4 2025), -$25.5 million (Q3 2025), and -$2.1 million (Q2 2025), per Business Quant data.